Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S

被引：50

作者：

Li, Qiannan ^{[1
]}

Zhang, Tao ^{[2
]}

Li, Shiliang ^{[1
]}

Tong, Linjiang ^{[2
]}

Li, Junyu ^{[1
]}

Su, Zhicheng ^{[1
]}

Feng, Fang ^{[2
]}

Sun, Deheng ^{[1
]}

Tong, Yi ^{[1
]}

Wang, Xia ^{[1
]}

Zhao, Zhenjiang ^{[1
]}

Zhu, Lili ^{[1
]}

Ding, Jian ^{[2
]}

Li, Honglin ^{[1
]}

Xie, Hua ^{[2
]}

Xu, Yufang ^{[1
]}

机构：

[1] East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2019年 / 10卷 / 06期

基金：

中国国家自然科学基金;

关键词：

EGFR; mutant; inhibitor; C797S; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; MUTATIONS; GEFITINIB; AZD9291;

D O I：

10.1021/acsmedchemlett.8b00564

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFR(L858R/T790M/C797S). One of the most promising compounds, 25g, inhibited the enzymatic activity of EGFR(L8S8R/T790M/C797S) with an IC50 value of 2.2 nM. Cell proliferation assays showed that 25g effectively and selectively inhibited the growth of EGFR(L858R/T790M/C797S)-dependent cells. This series of compounds, which occupy both the ATP binding site and the allosteric site of the EGFR kinase, may serve as a basis for the development of fourth-generation EGFR inhibitors for L858R/T790M/C797S mutants.

引用

页码：869 / 873

页数：9

共 50 条

[31] Identification of Novel Fourth-Generation Allosteric Inhibitors Targeting Inactive State of EGFR T790M/L858R/C797S and T790M/L858R Mutations: A Combined Machine Learning and Molecular Dynamics Approach
Bhanja, Kousik K.
Patra, Niladri
JOURNAL OF PHYSICAL CHEMISTRY B, 2025,
[32] Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer
Wang, Xiaoxue
Qin, Zhongxiang
Qiu, Wenrui
Xu, Kejia
Bai, Yuting
Zeng, Beilei
Ma, Yakun
Yang, Shuang
Shi, Yi
Fan, Yan
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277
[33] 虚拟筛选和鉴定EGFRL858R/T790M非共价抑制剂
郭超华
韩春
郑旭梅
赵琳
吴林韬
王志军
长治医学院学报, 2024, 38 (02) : 87 - 90
[34] Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers
Zhang, Jingya
He, Pengxing
Wang, Wenwen
Wang, Yuxing
Yang, Han
Hu, Zhaoxin
Song, Yihui
Chang, Junbiao
Yu, Bin
JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (05) : 5954 - 5972
[35] Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
Juchum, Michael
Guenther, Marcel
Doering, Eva
Sievers-Engler, Adrian
Laemmerhofer, Michael
Laufer, Stefan
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (11) : 4636 - 4656
[36] Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors
Hoogenboom, Niels
Demont, Dennis
de Zwart, Edwin
Verkaik, Saskia
Emmelot, Maaike
van de Kar, Bas
Kaptein, Allard
Barf, Tjeerd
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 52
[37] Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity
Akher, Farideh Badichi
Farrokhzadeh, Abdolkarim
Ravenscroft, Neil
Kuttel, Michelle M.
JOURNAL OF PHYSICAL CHEMISTRY B, 2020, 124 (28): : 5813 - 5824
[38] Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
Suriya, Utid
Mahalapbutr, Panupong
Wimonsong, Watchara
Yotphan, Sirilata
Choowongkomon, Kiattawee
Rungrotmongkol, Thanyada
MOLECULES, 2022, 27 (24):
[39] How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFRL858R/T790M/C797S Inhibitors: A Molecular Dynamics Simulation Study
Jingwen, E.
Liu, Ye
Guan, Shanshan
Luo, Zhijian
Han, Fei
Han, Weiwei
Wang, Song
Zhang, Hao
MOLECULES, 2020, 25 (04):
[40] EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
Rangachari, Deepa
To, Ciric
Shpilsky, Jason E.
VanderLaan, Paul A.
Kobayashi, Susumu S.
Mushajiang, Mierzhati
Lau, Christie J.
Paweletz, Cloud P.
Oxnard, Geoffrey R.
Janne, Pasi A.
Costa, Daniel B.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : 1995 - 2002

← 1 2 3 4 5 →